Bayer’s Internal Overhaul Gains Momentum While Investors Await Supreme Court’s Verdict
13.06.2026 - 07:14:09 | boerse-global.de
Bayer is running at two speeds. Inside the Leverkusen headquarters, management is executing a sweeping restructuring that touches everything from consumer health to radiology. On the trading floor, the stock remains pinned in place, waiting for a single event: the U.S. Supreme Court’s ruling on glyphosate liability. The gap between operational reality and market valuation has rarely been wider.
Strong Quarter Buried Under Legal Cloud
First-quarter 2026 results underscore the paradox. Bayer’s adjusted operating profit climbed 9% to €4.5 billion, beating consensus estimates. Group revenue on a currency-adjusted basis reached €13.4 billion. The agriculture division, the company’s largest, delivered a notable margin improvement, while the consumer health unit posted 5% growth. Management reaffirmed its full-year sales target of around €45 billion.
Yet the cash flow statement tells a less flattering story. Free cash flow swung to minus €2.3 billion, weighed down by large outflows for legal settlements. The cost of resolving past litigation continues to drain the balance sheet, even as the core businesses perform.
Leadership Reshuffle Accelerates
CEO Bill Anderson is moving quickly to reshape the executive team. Dr. Judith Hartmann took over as chief financial officer in early June. Dr. Jost Reinhard, previously head of investor relations, will lead the radiology division starting August 1, reporting directly to pharma board member Stefan Oelrich.
Should investors sell immediately? Or is it worth buying Bayer?
The most extensive changes are unfolding in the over-the-counter medicines unit. Four new senior managers are being brought in. Samantha Avivi assumes global marketing responsibilities. Analia de la Fuente becomes the unit’s first global chief data officer, tasked with embedding data analytics and artificial intelligence into decision-making. David Tomasi will run worldwide sales. The overhaul is designed to make the consumer health business faster and more agile — a structural pivot rather than a cosmetic refresh.
Stock Marking Time
None of this internal activity has stirred the share price. Bayer’s stock closed at €36.06 on Friday, leaving it down about 5% year to date. It sits almost exactly on its 200-day moving average of €35.99, a level that briefly broke earlier but has held. Short-term moving averages at €38 and €40 remain well above the current price, and the 31% volatility reading reflects deep nervousness among holders.
Analysts are cautious but not entirely bearish. Berenberg nudged its price target up to €40.50 from €40.00 while maintaining a “hold” rating. Analyst Sebastian Bray sees a 60% probability of a favorable Supreme Court outcome — essentially a coin toss.
Bayer at a turning point? This analysis reveals what investors need to know now.
The Ruling That Could Unlock Everything
The source of the market’s paralysis is Washington. The Supreme Court is scheduled to deliver its opinion in Durnell v. Bayer by the end of July, with a possible announcement as early as June 18, when the court holds its next opinion day. The case asks whether a state may impose penalties on the company for a product that the federal Environmental Protection Agency had already deemed safe.
A positive ruling would remove the single biggest overhang on Bayer’s equity. The company would suddenly emerge not just with a cleaner legal profile but with a reinforced management team, a healthier pipeline, and a business that is generating solid operational results. Until then, every buyer is making a bet on the justices, not on the fundamentals.
Ad
Bayer Stock: New Analysis - 13 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
